



Cellular and Immunotherapy for Acute Lymphoblastic Leukemia

Guest Editors:

Dr. Hisham Abdel-Azim

Keck School of Medicine,
Children Hospital Los
Angeles, University Of Southern
California, Los Angeles, CA, USA

Dr. Rachel Gallant

Children Hospital Los Angeles,
Los Angeles, CA, USA

Dr. Kris M. Mahadeo

MD Anderson Cancer Center,
University of Texas, Houston, TX,
USA

Deadline for manuscript
submissions:

closed (31 October 2022)

Message from the Guest Editors

Dear Colleagues,

Acute lymphoblastic leukemia (ALL) affects both adults and children and is the most common pediatric malignancy. ALL is traditionally treated with cytotoxic chemotherapy agents, yet despite improvement in outcomes there is still a subset of patients who do not respond or relapse after chemotherapy. Advances in cellular therapy and immunotherapy provide therapeutic alternatives or adjuncts to chemotherapy which is especially important for those with refractory or relapsed disease. This special issue will explore advances in the pathogenesis of Acute Lymphoblastic Leukemia and cellular and immunotherapy for the treatment of ALL including chimeric antigen receptor T-cell therapy and monoclonal antibody therapy.

Dr. Hisham Abdel-Azim

Dr. Rachel Gallant

Dr. Kris M. Mahadeo

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)